Full-Time
Global producer of crop nutrients
No salary listed
Yorkton, SK, Canada
In Person
Onsite role in Esterhazy, Saskatchewan.
Bachelor's, Master's
See people who can refer or advise you
Mosaic supplies crop nutrients and fertilizers to farmers worldwide. Its products are formulated to meet crop nutrient needs, helping fields grow with better yields by delivering essential nutrients through fertilizers and other soil amendments. The company operates in North and South America, employs over 13,000 people across six countries, and distributes products globally. Mosaic differentiates itself by focusing on sustainability and corporate citizenship, seeking to maximize efficiency and minimize environmental impact while maintaining transparent, ethical practices and strong ESG performance to build trust with customers and communities. The company’s goal is to support global food production by providing reliable, responsible fertilizer solutions that boost productivity while reducing environmental footprint.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Tampa, Florida
Founded
2004
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Health Savings Account/Flexible Spending Account
Tuition Reimbursement
Mosaic stock rises as analysts back margin recovery story. ELLIS HOBBS - UPDATED AUG. 21, 2026, 4:37 PM ET Mosaic Company (The) stocks have been trading up by 4.63 percent amid upbeat sentiment on stronger fertilizer demand and pricing. What traders need to know. * RBC Capital Markets reaffirmed an Outperform on Mosaic Company (The) with a $27 target, seeing a cyclical margin recovery ahead while free cash flow improves from lower capex and a working-capital tailwind into 2027. * BNP Paribas lifted its MOS price target to $32 and kept an Outperform rating, with overall analyst opinion overweight and clustered around a $27 average target. * Mizuho nudged its MOS target to $25 but stayed Neutral, showing improved yet still cautious sentiment on the fertilizer name. * Recent Q2 2026 adjusted EPS of $0.13 came in just above the $0.12 consensus, a modest beat in a weak pricing backdrop. * Management launched and then completed up to $1.4B of note repurchases and refinancings and rolled out Renuvis Enzara via Mosaic Biosciences, combining balance sheet cleanup with product innovation. Weekly Update Aug 17 - Aug 21, 2026: On Friday, August 21, 2026 Mosaic Company (The) stock [NYSE: MOS] is trending up by 4.63%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Materials industry expert: Analyst sentiment - positive Mosaic sits in the lower half of the global fertilizer cost curve, but current fundamentals are stressed. Q2 revenue annualizes to roughly flat versus 2024, with gross margin near 11% and negative EBIT, ROE, and net margin (LTM profit margin about -5%). Working-capital build and $317m capex drove negative Q2 FCF of ~$153m, leaving cash only $294m versus $1.44bn current debt and a thin 1.3x current ratio. The offset is low equity valuation: ~0.6x book and ~0.6x sales. Price action shows a sharp, high-volume momentum reversal: the stock moved from ~21.2 to 24.4 in five sessions, breaking multiple prior resistance bands and establishing a new short-term uptrend. Consecutive higher highs and higher lows on both daily and intraday 5-minute candles confirm aggressive dip-buying, especially on pullbacks near 22-23. The key actionable level is $23.00: above it, long bias with stops near 22.30; a decisive breakdown below 23.00 would signal exhaustion and a likely retest of the 21-22 zone. Fundamental and technical catalysts are turning favorable relative to Materials and Ag peers. Street targets cluster around $27-32 with predominantly Outperform ratings, reflecting confidence in phosphate margin recovery into 2027, tighter sulfur, and Mosaic's capex discipline plus debt-tender program de-risking the balance sheet. New biosciences products add optionality but are not thesis-critical. I see upside to $27 over 6-12 months, with support at $22 and strong resistance near $27-28. Quick financial overview. Mosaic Company (The) is trading in the mid-$20s, with weekly data showing a steady climb from roughly $21 to about $24. The stock's move from a $21.23 open early in the week toward a $24.43 close reflects a firm short-term uptrend. Intraday, MOS showed a controlled grind higher from the low $23s to the mid-$24s, with minor pullbacks being bought. For short-term traders, that intraday pattern signals demand on dips rather than panic selling. On the fundamentals, Mosaic Company (The) generated about $12.1B in trailing revenue, but margins are thin, with gross margin near 11% and recent net margins negative. Q2 2026 results showed revenue around $2.82B, a small gross profit and an operating loss, highlighting how tough fertilizer pricing has been. Still, adjusted EPS of $0.13 slightly topped expectations, which helps explain why analysts see MOS as an early-stage recovery rather than a broken story. Valuation leans supportive. With price-to-sales around 0.58 and price-to-book near 0.62, MOS trades at a discount to its asset base, typical for a cyclical trough. Balance sheet strength is reasonable, with total debt-to-equity at 0.54 and interest coverage of 6.3, and recent $1.4B note tenders further reduce near- and medium-term maturity risk. Cash flow is choppy, with recent free cash flow negative, but the company is targeting lower capex and an H2 working-capital reversal. A roughly 3.8% dividend yield adds carry for swing traders willing to sit through volatility. Conclusion. Mosaic Company (The) now sits at an interesting crossroads for active traders. The tape shows MOS pushing higher on the week, supported by a solid intraday uptrend and dip-buying behavior around the low $24s. At the same time, the financials confirm this is still a margin-compressed, cyclical name, not a clean growth story. That mix of improving price action against still-messy earnings is exactly where short-term setups can be most powerful. Street support adds fuel. RBC's Outperform call with a $27 target, backed by a margin recovery view into 2027, aligns with BNP Paribas' more aggressive $32 target and an overweight consensus around $27. The modest Q2 EPS beat, the $1.4B debt tender program, and the Renuvis Enzara launch all point to a management team working both the balance sheet and the product side. Yet negative recent net income and volatile free cash flow underline that MOS will not move in a straight line. For traders, MOS is a classic cyclical rebound candidate: cheap on sales and book, improving technically, but still hostage to fertilizer pricing and phosphate margins. That argues for trading plans with clear levels rather than blind conviction. This is exactly where discipline matters: chasing green candles in a choppy, cyclical name can be dangerous, no matter how compelling the narrative looks. As millionaire penny stock trader and teacher Tim Sykes, says, "There is always another play around the corner; don't chase just because you feel FOMO.". As I tell my students, "The edge in names like MOS comes from respecting the volatility, trading the levels, and letting the market confirm the recovery before you size up." This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: One-of-a-kind AI play revealed. If you'd put $2,000 into Nvidia back in 2020, you'd be sitting on more than $30,000 today. The stock's been an absolute monster... But if you think you missed the boat, then you need to see this urgent message TODAY. Because not only am I revealing why the REAL AI boom is only just getting started... I'm also going to show you my top AI recommendation that's been CRUSHING it in this market. It has nothing to do with Nvidia... or Meta... or OpenAI... or anything else you're probably thinking. It's a unique AI play I'm certain you're not hearing from anyone else... One that could give you the chance to target an entire YEAR of peak Nvidia potential... In just one day. How much has this post helped you? (0 votes, average: 0 out of 5)
The Mosaic Company has completed a $2.0 billion senior notes offering, issuing $1.0 billion of 5.350% notes due 2031, $500 million of 5.650% notes due 2034, and $500 million of 5.900% notes due 2036. Concurrently, Mosaic conducted tender offers for up to $1.4 billion of existing debt securities maturing between 2027 and 2029. The company used a portion of the proceeds to fund the tender offers and plans to allocate remaining funds for general corporate purposes, including potential debt repayment or refinancing. Mosaic is a leading producer and marketer of potash and phosphate fertiliser, which are essential agricultural inputs. Simpson Thacher represented the company in both transactions.
Mosaic Biosciences has launched Renuvis Enzara, a residue management solution using targeted enzyme technology to accelerate crop residue breakdown. The product addresses challenges from higher-yielding hybrids, no-till practices, and continuous corn that increase residue levels, potentially narrowing planting windows and reducing operational efficiency. Enzara uses endoglucanase enzyme technology that functions in temperatures as low as 32 degrees Fahrenheit, targeting structural fibres in crop residue. The solution can be applied in autumn or spring and is tank-mix compatible with existing fertiliser and herbicide applications. In 2025 on-farm trials, Enzara demonstrated improvements in residue decomposition in corn-on-corn and soybean-after-corn systems, with spring applications improving emergence, stand count, and uniformity in both crops. The product suits various production systems, including no-till, reduced-till, and conventional tillage operations.
Florida scrub jays move into Myakka City. A conservation partnership aims to improve the threatened species' long-term viability in Manatee County. * By Lesley Dwyer * | 7:02 p.m. August 10, 2026 * East County * News Florida scrub jays are not the typical fair-weather avian friends that fly north in the spring. The blue and gray birds are endemic to Florida. As their name suggests, scrub jays live in Florida's sandy, scrub habitats. The Florida Fish and Wildlife Conservation Commission reported the scrub jay population has declined 90% in the past century due to habitat loss and fragmentation because of development and agriculture. The Florida Department of Environmental protection estimates the current scrub jay population at between 7,000 and 9,300 birds. The species federal status is "threatened." In January, Wingate Creek State Park in Myakka City welcomed 48 scrub jays from three separate locations around Florida: 16 from Central Florida's Archbold Biological Station, 16 from the East Coast's Cape Canaveral Space Force Station and 16 from Manatee County's Duette Preserve. The project is a public-private partnership between the U.S. Fish and Wildlife Service, the University of Central Florida, the Archbold Biological Station, The Mosaic Company and Verdantas. The aim of the project is to enhance genetic diversity and improve the species' long-term viability in the region. Raoul Boughton, Ph.D., senior manager of ecology & wildlife for The Mosaic Company, noted that researchers thought scrub jays would disappear entirely from Manatee County because the birds were too closely related. "They didn't want to pair up with each other; they didn't want to breed," Boughton said. "We are probably going to be the first area that actually meets recovery. (Recovery) is a U.S. Fish and Wildlife Service term, where they've set a goal for the population to meet." The goal is for the species to be viable for the next 100 years. Only young birds entering their first breeding season were relocated to give the birds the greatest opportunity to establish territories, choose mates and successfully integrate into the new population. Just six months after the relocation, the team documented 10 likely breeding pairs, six new nests and four nests with eggs. The relocated birds have established territories throughout the park and formed 11 family groups. Researchers estimate the project could add up to 12 new breeding pairs to the park over the next three years.
The Mosaic Company reported a second-quarter net loss of $273 million, or 86 cents per share, down from a $411 million profit in the prior year. Adjusted earnings of 13 cents per share beat the consensus estimate of 9 cents but fell 74.5% year over year. Net sales declined 6% to $2.82 billion, missing the $3.05 billion estimate. Lower sales volumes and elevated raw material costs, particularly sulphur, offset higher phosphate and potash prices. The Phosphate segment posted $1.25 billion in sales but saw gross margin turn negative at $4 per tonne from $67 per tonne previously. Potash segment sales fell to $650 million with volumes dropping to 2 million tonnes from 2.3 million tonnes. Mosaic ended the quarter with $294 million in cash and long-term debt of $4.77 billion. The company generated negative free cash flow of $152.9 million.